title: Mitochondrial potassium channels as pharmacological target for cardioprotective drugs.
abstract: Brief periods of ischemia are known to confer to the myocardium an increased resistance to the injury due to a later and more prolonged ischemic episode. This phenomenon, known as ischemic preconditioning (IPreC), is ensured by different biological mechanisms. Although an exhaustive comprehension of them has not been reached yet, it is widely accepted that mitochondria are pivotally involved in controlling cell life and death, and thus in IPreC. Among the several signaling pathways involved, as triggers and/or end effectors, in the mitochondrial mechanisms of cardioprotection, an important role is played by the activation of potassium channels located in the mitochondrial inner membrane (mitoK) of cardiomyocytes. Presently, different types of mitoK channels have been recognized in the heart, such as ATP-sensitive (mitoKATP) and calcium-activated (mitoBK(Ca) and mitoSK(Ca)) potassium channels. Consistently, drugs modulating mitoK, on one hand, have been employed as useful experimental tools for early basic studies on IPreC. On the other hand, activators of mitoK are promising and innovative therapeutic agents for limiting the myocardial injury due to ischemic episodes. In this review, we report the experimental evidence supporting the role of mitoK in signaling pathways in the mechanisms of cardioprotection and an overview on the most important molecules acting as modulators of these channels, with their profiles of selectivity. Some innovative pharmaceutical strategies for mitochondriotropic drugs have been also reported. Finally, an appendix describing the main experimental approaches usually employed to study mitoK in isolated mitochondria or in intact cells has been added.
authors.affiliation: Department of Pharmacy, University of Pisa, Pisa, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Testai
authors.forename: S
authors.initials: S
authors.lastname: Rapposelli
authors.forename: A
authors.initials: A
authors.lastname: Martelli
authors.forename: M C
authors.initials: MC
authors.lastname: Breschi
authors.forename: V
authors.initials: V
authors.lastname: Calderone
mesh_terms: D000818:Animals; D002118:Calcium / Q000737:chemistry; D002316:Cardiotonic Agents / Q000737:chemistry*; D016923:Cell Death; D006801:Humans; D057775:Ischemic Postconditioning; D019194:Ischemic Preconditioning; D051379:Mice; D008928:Mitochondria / Q000378:metabolism* / Q000473:pathology; D008929:Mitochondria, Heart / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D015221:Potassium Channels / Q000378:metabolism*; D015427:Reperfusion Injury; D015398:Signal Transduction
chemical_list: D002316:Cardiotonic Agents; D015221:Potassium Channels; C117780:mitochondrial K(ATP) channel; D002118:Calcium
keywords: cardioprotective drugs; ischemia-reperfusion; mitochondrial potassium channels; myocardial injury; potassium channel activators